These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36167561)

  • 1. [Drug approval: Mosunetuzumab - third-line therapy in follicular lymphoma].
    Gondran C; Ysebaert L
    Bull Cancer; 2022 Nov; 109(11):1105-1106. PubMed ID: 36167561
    [No Abstract]   [Full Text] [Related]  

  • 2. Mosunetuzumab: First Approval.
    Kang C
    Drugs; 2022 Jul; 82(11):1229-1234. PubMed ID: 35947358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
    Matarasso S; Assouline S
    Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting.
    Cao Y; Marcucci EC; Budde LE
    J Hematol Oncol; 2023 Jun; 16(1):69. PubMed ID: 37381053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma.
    Nierengarten MB
    Cancer; 2023 May; 129(10):1465-1466. PubMed ID: 37088993
    [No Abstract]   [Full Text] [Related]  

  • 6. Bispecific antibodies in indolent B-cell lymphomas.
    Radhakrishnan VS; Davies AJ
    Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on bi-specific monoclonal antibodies for blood cancers.
    Shouse G
    Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
    Budde LE; Sehn LH; Matasar M; Schuster SJ; Assouline S; Giri P; Kuruvilla J; Canales M; Dietrich S; Fay K; Ku M; Nastoupil L; Cheah CY; Wei MC; Yin S; Li CC; Huang H; Kwan A; Penuel E; Bartlett NL
    Lancet Oncol; 2022 Aug; 23(8):1055-1065. PubMed ID: 35803286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
    Bosch F; Kuruvilla J; Vassilakopoulos TP; Maio DD; Wei MC; Zumofen MB; Nastoupil LJ
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):105-121. PubMed ID: 37981564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
    Maurer MJ; Casulo C; Larson MC; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P; Cohen JB; Kahl BS; Burack WR; Koff JL; Mun Y; Masaquel A; Wu M; Wei MC; Shewade A; Li J; Cerhan JR; Link BK; Flowers CR
    Haematologica; 2024 Jul; 109(7):2177-2185. PubMed ID: 38031804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
    Liu X; Zhao J; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mosunetuzumab (Lunsumio) for follicular lymphoma.
    Med Lett Drugs Ther; 2023 Mar; 65(1671):e41-e42. PubMed ID: 36877285
    [No Abstract]   [Full Text] [Related]  

  • 13. The landscape of T-cell engagers for the treatment of follicular lymphoma.
    Rivas-Delgado A; Landego I; Falchi L
    Oncoimmunology; 2024; 13(1):2412869. PubMed ID: 39398477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.
    Buske C
    Lancet Oncol; 2022 Aug; 23(8):967-969. PubMed ID: 35803285
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
    González Barca E
    Front Immunol; 2022; 13():909008. PubMed ID: 35928819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
    Matsuda I; Hirota S
    Int J Clin Exp Pathol; 2015; 8(8):9737-41. PubMed ID: 26464748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New European approval: Duvelisib - relapsed/refractory CLL and follicular lymphoma].
    Fornero L; Lamure S
    Bull Cancer; 2021 Oct; 108(10):906-907. PubMed ID: 34607678
    [No Abstract]   [Full Text] [Related]  

  • 19. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
    Feugier P
    Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Therapies for Follicular Lymphoma.
    Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
    Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.